Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs BINOSTO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men,Treatment of glucocorticoid-induced osteoporosis,Prevention of osteoporosis in postmenopausal women
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
70 mg orally once weekly
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is approximately 10 hours; clinical context: supports once-weekly dosing for osteoporosis
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Not metabolized; excreted unchanged primarily via renal clearance.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal: 50% excreted unchanged in urine; fecal: 20% as unabsorbed drug; biliary: negligible
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 24% bound to plasma proteins (primarily albumin)
4-6 L/kg; large Vd indicates extensive tissue distribution
Vd: 0.2 L/kg; clinical meaning: low distribution, confined primarily to plasma and bone surface
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 0.7% (range 0.4–1.0%) when taken with plain water under fasting conditions
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Cr Cl <35 m L/min: not recommended; Cr Cl 35-60 m L/min: no adjustment needed; Cr Cl >60 m L/min: no adjustment needed
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment
Not approved for pediatric patients <18 years; safety and efficacy not established.
Not approved for pediatric use (safety and efficacy not established)
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment; consider renal function and comorbidities
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Risk of atypical femur fractures,Osteonecrosis of the jaw,Severe musculoskeletal pain,Hypocalcemia,Renal impairment,Esophageal irritation or ulceration if not taken properly
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypocalcemia,Inability to stand or sit upright for at least 30 minutes,Severe renal impairment (Cr Cl <30 m L/min),Esophageal abnormalities that delay esophageal emptying
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Food, beverages (including mineral water, coffee, orange juice, and milk), and other oral medications significantly reduce absorption. Must be taken with plain water only on an empty stomach. Avoid high-calcium foods (e.g., dairy, fortified juices) within 30 minutes of dosing. Separate from calcium supplements, antacids, and iron supplements by at least 30 minutes.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Bisphosphonates, including BINOSTO (alendronate), are not recommended during pregnancy. First trimester: Limited data suggest no significant increase in major malformations, but risk cannot be excluded due to small sample sizes. Second and third trimesters: Potential risk of fetal skeletal abnormalities due to calcium homeostasis disruption. Alendronate is classified as FDA Pregnancy Category C.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Alendronate is excreted into human breast milk in low amounts; M/P ratio unknown. Due to potential for bone growth suppression in the infant, breastfeeding is not recommended during therapy. Consider alternative treatments if breastfeeding is necessary.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No dose adjustments are recommended during pregnancy as the drug is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) may alter alendronate exposure, but no studies have evaluated dose modifications. Therapy should be discontinued if pregnancy is planned or confirmed.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Binosto (alendronate sodium effervescent tablet) is a bisphosphonate for osteoporosis. Administer immediately after dissolving in at least 4 oz of room temperature water; do not chew or suck tablets. Give at least 30 minutes before first food, beverage, or other medication of the day to ensure absorption and reduce esophageal irritation. Monitor for hypocalcemia and renal function (Cr Cl <35 m L/min contraindicated). Discontinue if severe bone, joint, or muscle pain occurs. Consider drug holidays after 5 years for low-risk patients.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take Binosto first thing in the morning on an empty stomach with a full glass of plain water (4-6 oz). Do not use mineral water or other beverages.,Wait at least 30 minutes after taking the tablet before eating, drinking, or taking any other medications.,Dissolve the tablet completely in water before drinking. Do not chew or swallow the tablet whole.,Stay upright (sitting or standing) for at least 30 minutes after taking to prevent esophageal irritation.,Swallow quickly after dissolution to avoid incomplete dosing.,Report any difficulty swallowing, pain when swallowing, retrosternal pain, or new/worsening heartburn.,Take calcium and vitamin D supplements as directed, but separate from Binosto by at least 30 minutes.,Rapid weight loss or prolonged immobility may increase risk of adverse effects.,Annual dental exams and good oral hygiene are recommended; report any jaw pain or delayed healing after dental procedures.,Do not double the dose if missed; skip it and take the next day's dose as usual.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs BINOSTO, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. BINOSTO is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and BINOSTO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of BINOSTO is: 70 mg orally once weekly. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and BINOSTO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. BINOSTO is classified as Category C. Bisphosphonates, including BINOSTO (alendronate), are not recommended during pregnancy. First trimester: Limited data suggest no significant increase in major malformations, but ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.